Table 3 Matched comparison of ibrutinib-treated patients and controls receiving conventional chemotherapies
Ibrutinib-treated patients (n = 63) | Control patients (n = 63) | P value | |
|---|---|---|---|
Age in years, median [IQR] | 74 [66–78] | 72 [66–78] | 0.895 |
Male gender, n (%) | 40 (63) | 42 (66) | 0.852 |
Prior chemotherapy lines, n (%) | < 0.001 | ||
0 | 7 (12) | 15 (24) | |
1 | 22 (36) | 23 (37) | |
2 | 18 (30) | 6 (10) | |
3 | 11 (18) | 12 (19) | |
≥ 4 | 3 (4) | 6 (9) | |
Prior chemotherapy lines, median [IQR] | 2 [1–2] | 0 [0–2] | 0.001 |
Underlying disease, n (%) | 0.881 | ||
CLL | 41 (65) | 40 (64) | |
DLBCL | 9 (14) | 11 (18) | |
Others | 13 (21) | 12 (19) | |
Additional risk factors, n (%) | |||
Diabetes | 11 (18) | 12 (19) | 1.000 |
HIV | 1 (2) | 1 (2) | 1.000 |
SOFA score at ICU admission, median [IQR] | 5 [3–8] | 7 [5–10] | 0.065 |
Organ injury at ICU admission, n (%) | |||
Respiratory | 45 (71) | 49 (79) | 0.401 |
Hemodynamic | 32 (50) | 33 (52) | 0.858 |
Liver | 12 (19) | 0 (0) | < 0.001 |
Renal | 21 (33) | 19 (30) | 0.710 |
Neurological | 27 (43) | 12 (19) | 0.004 |
Multiorgan failure | 43 (68) | 40 (64) | 0.571 |
Organ support throughout ICU stay, n (%) | |||
Invasive mechanical ventilation | 26 (41) | 39 (62) | 0.032 |
Vasopressors | 35 (56) | 44 (70) | 0.141 |
RRT | 9 (14) | 5 (8) | 0.395 |
Diagnostic group, n (%) | 0.004 | ||
Bacterial infection | 39 (62) | 55 (87) | 0.039 |
Viral infection | 11 (17) | 3 (5) | 0.027 |
Fungal infection | 13 (21) | 5 (8) | 0.001 |
ICU mortality, n (%) | 17 (27) | 24 (38) | 0.254 |
Day-90 mortality, n (%) | 30 (52) | 29 (48) | 0.785 |